Akebia Therapeutics, Inc. reported a net loss of $9.1 million, or $0.03 per share, for the quarter ended March 31, 2026, compared to a net income of $6.1 million, or $0.03 per share, for the same period in 2025. Total revenues decreased by 7% to $53.5 million, primarily driven by a decrease in product revenue, which fell from $55.8 million to $52.0 million. This decline in product revenue was partially offset by an increase in license, collaboration, and other revenue, which rose slightly from $1.545 million to $1.552 million. The number of common shares outstanding as of May 4, 2026, was 268,258,243.
The decrease in product revenue was attributed to lower Auryxia sales, partially offset by increased Vafseo sales. Auryxia sales were $36.2 million compared to $43.8 million in the prior year, reflecting the impact of generic competition following the loss of exclusivity in March 2025. Vafseo sales increased from $12.0 million to $15.8 million. Cost of product and other revenue increased significantly, rising 61% to $12.3 million, primarily due to increased inventory write-downs. Research and development expenses also increased by 52% to $14.8 million, driven by increased clinical trial activities related to praliciguat and AKB-9090, as well as higher headcount-related costs. Selling, general, and administrative expenses increased by 18% to $30.4 million, also driven by higher headcount-related costs.
Akebia's strategic developments included the ongoing commercialization of Vafseo and Auryxia, as well as the advancement of its pipeline assets. The company initiated a Phase 1 clinical trial of AKB-9090 for the treatment of cardiac surgery-related acute kidney injury (CS-AKI) in April 2026 and dosed the first patient in a Phase 2 clinical trial of praliciguat for focal segmental glomerulosclerosis (FSGS) in December 2025. On January 27, 2026, Akebia entered into a lease agreement for a new corporate headquarters in Waltham, Massachusetts, with relocation expected in September 2026. Teva Pharmaceuticals Ltd. received approval for its Abbreviated New Drug Application for a generic version of Auryxia, which has subsequently entered the market.
Operationally, Akebia reported cash and cash equivalents of $162.6 million as of March 31, 2026, a decrease from $184.8 million at the end of 2025. The company believes its cash resources, along with anticipated revenue from product sales, royalties, and collaborations, will be sufficient to fund its operating plan for at least the next twelve months. However, this is contingent on achieving projected Vafseo revenue targets. Akebia may explore additional financing options, including public or private equity offerings, debt transactions, or strategic collaborations. The company's future performance is subject to various risks, including competition, regulatory approvals, and the ability to maintain key contracts and collaborations.
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for kidney disease. Its core products include Vafseo, an oral treatment for anemia due to chronic kidney disease (CKD) in dialysis patients, and Auryxia, an oral medicine for hyperphosphatemia and iron deficiency anemia in CKD patients. Akebia leverages hypoxia-inducible factor (HIF) science and targets nephrology markets through direct sales and partnerships globally.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.